Deutsche Bank AG Increases Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Deutsche Bank AG boosted its holdings in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 468.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,995 shares of the company’s stock after purchasing an additional 79,940 shares during the period. Deutsche Bank AG owned about 0.16% of Acumen Pharmaceuticals worth $167,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ABOS. Susquehanna Fundamental Investments LLC purchased a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $25,000. Clune & Associates LTD. bought a new stake in Acumen Pharmaceuticals during the 4th quarter valued at approximately $28,000. Intech Investment Management LLC bought a new stake in Acumen Pharmaceuticals during the 4th quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its position in Acumen Pharmaceuticals by 427.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock valued at $35,000 after acquiring an additional 16,714 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock valued at $44,000 after acquiring an additional 7,859 shares in the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS opened at $1.00 on Tuesday. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average price is $1.04 and its 200-day moving average price is $1.45. Acumen Pharmaceuticals, Inc. has a 52 week low of $0.86 and a 52 week high of $3.60. The stock has a market cap of $60.57 million, a P/E ratio of -0.72 and a beta of 0.09.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. During the same period in the prior year, the firm earned ($0.25) earnings per share. Equities research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ABOS shares. UBS Group cut their price objective on Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 28th. HC Wainwright cut their price objective on Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, March 28th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.